<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478607</url>
  </required_header>
  <id_info>
    <org_study_id>E05-CL-3002</org_study_id>
    <secondary_id>2009-016458-42</secondary_id>
    <nct_id>NCT01478607</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients</brief_title>
  <acronym>PACE</acronym>
  <official_title>A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety of repeated applications of QUTENZA in
      reducing pain intensity in subjects who have peripheral neuropathic pain due to diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be divided into 3 groups of approximately equal size. In the first group,
      patients will receive a QUTENZA patch applied for 30 minutes to the feet; in the second
      group, patients will receive a QUTENZA patch applied for 60 minutes to the feet. In both
      these groups patients will also continue to receive their normal treatment (Standard of Care
      (SOC)) for their peripheral neuropathic pain (PNP) and may receive further QUTENZA patch
      applications in the same way during the study. The third group will not receive a QUTENZA
      patch but will continue to receive their normal treatment for their neuropathic pain (SOC).
      Subjects will be involved in the study for up to 15 months and will have to visit the clinic
      at least 9 times.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale</measure>
    <time_frame>Baseline till endpoint (discontinuation or End of Study visit) (up to 64 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological function as assessed by the Utah Early Neuropathy Scale (UENS) and sensory testing</measure>
    <time_frame>Baseline till End of Study (up to 64 weeks)</time_frame>
    <description>Physicians measuring neurological function will be blinded to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of patch application by dermal assessment</measure>
    <time_frame>Screening till Last visit when QUTENZA patch is applied (up to 53 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of patch application by &quot;pain now&quot; Numeric Pain Rating Scale (NPRS) scores after patch application</measure>
    <time_frame>Baseline till Last visit when QUTENZA patch is applied (up to 52 weeks)</time_frame>
    <description>Assessed within 15 minutes and 60 minutes after patch removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of patch application by rescue medication use</measure>
    <time_frame>Days 1 through 5 after each patch application</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and serious adverse Events</measure>
    <time_frame>Screening visit through End of study visit (up to 65 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (heart rate and blood pressure)</measure>
    <time_frame>Screening visit through End of study visit (up to 65 weeks)</time_frame>
    <description>In case of patch application to be performed within 15 minutes before topical anesthetic application and within 15 minutes after patch removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>Screening visit through End of study visit (up to 65 weeks)</time_frame>
    <description>The tests performed at the screening visit will include Hematology: Red Blood Cell Count, White Blood Cell Count, Lymphocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Hemoglobin, Hematocrit and Platelets. Biochemistry: Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT), Alkaline Phosphatase, Sodium, Potassium, Blood Urea Nitrogen (BUN), Creatinine and Lipid profile. Subsequent HbA1c and lipid profile follow-up will be done at bi-monthly visits. The other tests will be performed if clinically indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of neuropathic pain using &quot;average pain&quot; NPRS scores</measure>
    <time_frame>Screening visit through End of study visit (up to 65 weeks)</time_frame>
    <description>Question 5 of Brief Pain Inventory-Diabetic Neuropathy (BPI-DN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) pain severity index and pain interference index</measure>
    <time_frame>Screening visit through End of study visit (up to 65 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>After each patch re-application, from first patch re-application through End of Study visit (up to 56 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic HRQOL measured by European Quality of Life - 5 Dimensions (EQ-5D) questionnaire</measure>
    <time_frame>After each patch application, from first patch application through End of Study (up to 64 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit</measure>
    <time_frame>End of Study (up to 65 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Painful Diabetic Peripheral Neuropathy (PDPN)</condition>
  <arm_group>
    <arm_group_label>1. Qutenza 30 minutes + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Qutenza 60 minutes + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. SOC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QUTENZA</intervention_name>
    <description>A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).</description>
    <arm_group_label>1. Qutenza 30 minutes + SOC</arm_group_label>
    <arm_group_label>2. Qutenza 60 minutes + SOC</arm_group_label>
    <other_name>Capsaisin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy which is due to
             diabetes

          -  Stable glycemic control for at least 6 months prior to screening visit

          -  Average Numeric Pain Rating Scale (NPRS) score over the last 24 hours of &gt;4 at the
             screening and the baseline visit

        Exclusion Criteria:

          -  Primary pain associated with PDPN in the ankles or above

          -  Pain that could not be clearly differentiated from, or conditions that might interfere
             with, the assessment of PDPN

          -  Significant pain (moderate or above) of an etiology other than PDPN, that may
             interfere with judging PDPN-related pain

          -  Female subjects of childbearing potential must have a negative serum or urine
             pregnancy test at enrollment and must agree to maintain highly effective birth control
             during the study.

          -  Hypersensitivity to capsaicin (i.e., chili peppers or over-the-counter [OTC] capsaicin
             products), any QUTENZA excipients, Eutectic Mixture of Local Anesthetics( EMLA)
             ingredients or adhesives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Clinical Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 601</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 903</name>
      <address>
        <city>Beroun</city>
        <zip>26601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 910</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 908</name>
      <address>
        <city>Chocen</city>
        <zip>56501</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 911</name>
      <address>
        <city>Litomerice</city>
        <zip>41201</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 906</name>
      <address>
        <city>Ostrava</city>
        <zip>71000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 904</name>
      <address>
        <city>Policka</city>
        <zip>57201</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 901</name>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 902</name>
      <address>
        <city>Prerov</city>
        <zip>75003</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 909</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>51601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 207</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 202</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 201</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 206</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 508</name>
      <address>
        <city>Chiemsee</city>
        <zip>83209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 502</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 501</name>
      <address>
        <city>Falkensee</city>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 514</name>
      <address>
        <city>Frankfurt</city>
        <zip>60311</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 507</name>
      <address>
        <city>Hamburg</city>
        <zip>22177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 509</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 505</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 506</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 512</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 404</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 401</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 651</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 965</name>
      <address>
        <city>Bialystok</city>
        <zip>15435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 961</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85822</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 957</name>
      <address>
        <city>Elblag</city>
        <zip>82300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 958</name>
      <address>
        <city>Gdynia</city>
        <zip>81049</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 954</name>
      <address>
        <city>Katowice</city>
        <zip>40954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 964</name>
      <address>
        <city>Krakow</city>
        <zip>31530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 951</name>
      <address>
        <city>Lodz</city>
        <zip>90153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 966</name>
      <address>
        <city>Lubin</city>
        <zip>59300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 953</name>
      <address>
        <city>Poznan</city>
        <zip>61655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 959</name>
      <address>
        <city>Torun</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 960</name>
      <address>
        <city>Warszawa</city>
        <zip>1868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 714</name>
      <address>
        <city>Kemerovo</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 708</name>
      <address>
        <city>Samara</city>
        <zip>79117778999</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 709</name>
      <address>
        <city>Saratov</city>
        <zip>79117120826</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 703</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 716</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 704</name>
      <address>
        <city>St. Petersburg</city>
        <zip>79117120826</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 706</name>
      <address>
        <city>St. Petersburg</city>
        <zip>79117778999</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 713</name>
      <address>
        <city>Tomsk</city>
        <zip>79117778999</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 711</name>
      <address>
        <city>Yaroslavl</city>
        <zip>79117778999</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 303</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 304</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 305</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 808</name>
      <address>
        <city>Chernihiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 803</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 812</name>
      <address>
        <city>Kvuv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 805</name>
      <address>
        <city>Kyiv</city>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 807</name>
      <address>
        <city>Kyiv</city>
        <zip>4053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 806</name>
      <address>
        <city>Kyiv</city>
        <zip>4114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 810</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 802</name>
      <address>
        <city>Mykolayiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 801</name>
      <address>
        <city>Odesa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 813</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 815</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 102</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 1PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 103</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 104</name>
      <address>
        <city>Poole</city>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 101</name>
      <address>
        <city>Rugby</city>
        <zip>CV22 5PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016458-42/results</url>
    <description>Link to results on EudraCT</description>
  </link>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=E05-CL-3002</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Painful Diabetic Peripheral Neuropathy</keyword>
  <keyword>Qutenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

